3.3 C
New York

Bruker Acquires Nanophoton Corporation, a Japanese Technology Leader in Research Raman Microscopy with 20 Years of Experience

Published:

Nanophoton Strengthens Bruker’s Portfolio of Molecular Microscopy Research Solutions

OSAKA, Japan–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced Raman microscopes, serving academic and industrial research customers, primarily in Japan. This acquisition fills a gap in Bruker’s molecular microscopy portfolio, and Bruker is looking forward to offering fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.

Nanophoton RAMANtouch

Bruker logo

Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience. The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.

Professor Satoshi Kawata, the CEO founder of Nanophoton, commented: “We recently celebrated our 20th anniversary of Nanophoton and are delighted to open a new chapter in our history together with Bruker. Bruker is the ideal partner for Nanophoton to accelerate our growth, bring our unique Raman systems to customers worldwide and to develop unparalleled Raman imaging technologies together.”

Dr. Andreas Kamlowski, the President of the Bruker Optics division, added: “We warmly welcome the Nanophoton team to Bruker, and acknowledge their outstanding track record and expertise in innovating in Raman microscopy. We are look forward to this new opportunity to bring the differentiated Nanophoton Raman imaging systems to our research customers worldwide with global support.”

Financial terms of the transaction were not disclosed. In 2023, Nanophoton Corporation had revenues of approximately $5 million, and was near break-even.

About Nanophoton

Nanophoton was founded in 2003 as the world’s only dedicated Raman microscope manufacturer. Nanophoton has developed, manufactured, and sold unique laser-scanning Raman microscopes, including a line-illumination confocal Raman microscope that reduces measurement time by several hundred times and a Raman microscope that employs a unique beam-scanning method based on stochastic process and information theories. Other products Nanophoton has commercialized include the Raman microscopes for deep ultraviolet, for 30-cm wafers, and for long depth of focus imaging. The company also markets unique optical components such as speckle reducers and radial/azimuthal polarizers. Nanophoton has received overwhelming support from many customers, especially in Japan and Korea. For more information, please visit: www.nanophoton.jp, or www.nanophoton.net.

About Bruker Corporation

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com

Contacts

Investors:
Justin Ward

Sr. Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Media:
Michael Mueller

Marketing Manager

Bruker Optics GmbH & Co. KG

T: +49 7243 504 2652

Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Related articles

Recent articles

spot_img